TITLE

Can-Fite: therapeutic approach bolstered by positive results in psoriasis trial

PUB. DATE
October 2009
SOURCE
PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p18
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports on the positive outcome of the psoriasis trial of Israel-based biopharmaceutical firm Can-Fite Biopharma Ltd. The 75-patient Phase II double-blind clinical study of the anti-TNF drug CF101 in patients with moderate to severe psoriasis resulted to efficacy upon oral administration in 35% of the subjects. Accordingly, it was found that the small molecule CF101 is a promising oral anti-TNF agent that provides a well tolerated and safe therapeutic approach against the disease.
ACCESSION #
44767509

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;8/2/2011, Vol. 22 Issue 148, p7 

    The article reports on the enrollment in a Phase II/III trial of CF101, a drug for psoriasis, developed by Can-Fite BioPharma Ltd.

  • Dermatology.  // CenterWatch Weekly;4/6/2015, Vol. 19 Issue 13, p9 

    This article discusses the results of a phase II/III trial by pharmaceutical company Can-Fite BioPharma on the efficacy of the drug CF101 in patients with moderate-to-severe plaque psoriasis.

  • Quality of life. Gagnon, Louise // Dermatology Times;Mar2009, Vol. 30 Issue 3, p49 

    The article discusses the use of combination therapy in treating psoriasis. It explains the use of methotrexate systemic retinoids or phototherapy as part of a combined therapy with biologic agents for treating psoriasis. According to Doctor Alan Menter, chairman of the psoriasis research unit...

  • CLINIC ROUNDUP.  // BioWorld Today;9/17/2009, Vol. 20 Issue 179, p9 

    The article offers news briefs related to pharmaceutical industry. Israel-based Can-Fite BioPharma completed its Phase II study on CF101 drug designed to cure psoriasis. The Seattle, Washington-based Cell Therapeutics Inc. accomplished its purpose in the Phase III study called EXTEND aimed at...

  • Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs. Lerche, Catharina M.; Wulf, Hans Christian // Dermatology Reports;2010, Vol. 2 Issue 3, p32 

    Topical therapies constitute the mainstay of dermatological treatments for skin disorders, such as atopic dermatitis, contact dermatitis, psoriasis, or acne. Since some of these diseases are often chronic, treatment duration may last for years and may even last the patient's entire lifetime....

  • Therapeutic Moisturizers as Adjuvant Therapy for Psoriasis Patients. Gelmetti, Carlo // American Journal of Clinical Dermatology;2009 Supplement, Vol. 10 Issue S1, p7 

    At any point in time, psoriasis affects 2-3% of the world's population and has one of the biggest impacts on quality of life of any dermatological disorder. Treatment is extremely costly and prevention of disease progression in severity and extent is crucial. Psoriasis treatment should include...

  • DERMATOLOGICAL DISORDERS.  // Monthly Prescribing Reference;Feb2011, Vol. 27 Issue 2, p122 

    A part of the book "Monthly Prescribing Reference" for February 2011 is presented. It offers an overview of pharmacological treatments for dermatological disorders including acne, psoriasis and skin infections. The drugs include Aczone from Allergan, Neoral from Novartis and Abreva from...

  • Psoriasis.  // British Journal of School Nursing;Jun2014, Vol. 9 Issue 5, p222 

    The article offers information on the medical condition called psoriasis. Topics discussed include the physical symptoms and causes of psoriasis, the different types of psoriasis, and recommended treatments. It cites several topical treatments for the skin disease such as Calcipotriol vitamin D,...

  • Fusion protein denileukin diftitox clears psoriasis. Kuznar, Wayne // Dermatology Times;Oct2001, Vol. 22 Issue 10, p18 

    Reports the effectiveness of dermatologic agents denileukin diftitox in clearing skin lesions in patients with psoriasis vulgaris in New York. Antipsoriatic activity of denileukin; Daily dosage administration; Decrease of lesional T-cells in the dermis.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics